ORGANIZATION

7 EFPIA Companies Revised R&D Strategies after April Pricing Overhaul: Survey

November 9, 2018
Japan’s drug pricing overhaul in April has prompted 50% of EFPIA Japan member companies affected by policy changes to revise their R&D strategy in the country by September, according to a survey conducted by the trade group. EFPIA Japan, or…

To read the full story

Related Article

ORGANIZATION

By Reiji Anasako

Kyowa Hakko Kirin’s first and only Rituxan (rituximab) biosimilar in Japan is showing a faster-than-expected uptake in the market, with the company racking up 4.3 billion yen from the cancer drug in 2018, far beyond its initial 3.2 billion yen…

Members of a key reimbursement policy panel appear to be becoming more and more open to the industry’s call for…

By Philip Carrigan

With a cursory glance, recruitment is easily defined. We’re here to help place candidates into the vacancies our clients need to fill. Armed with a pen and paper, you could even map out the process.• We study the market• We…

By Shinya Sato

As 2019 rolls in, we expect to see a flurry of approvals in the Japanese regenerative medicine arena, with regulatory decisions anticipated by the end of the year for Novartis Pharma’s CAR-T therapy and many more products, which could bring…